Martijn Kleijwegt
Directeur/Bestuurslid bij OCULIS HOLDING AG
Vermogen: 24 M $ op 30-04-2024
Oorsprong van het eerstegraads netwerk van Martijn Kleijwegt
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
University of Amsterdam
35
| College/University | Other Consumer Services | 35 |
LSP Management Group BV
 LSP Management Group BV Investment ManagersFinance LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies.
34
| Subsidiary | Investment Managers | 34 |
| Public Company | Biotechnology | 26 | |
EQT Life Sciences Group BV
 EQT Life Sciences Group BV Investment ManagersFinance EQT Life Sciences Group BV (EQT Life Sciences) is a venture capital firm, a subsidiary of EQT AB founded in 2022 after the acquisition of LSP by EQT. The firm is headquartered in Amsterdam, the Netherlands.
22
| Subsidiary | Investment Managers | 22 |
| Public Company | Pharmaceuticals: Major | 13 | |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands.
12
| Holding Company | Biotechnology | 12 |
| Public Company | Pharmaceuticals: Major | 11 | |
Arvelle Therapeutics International GmbH
 Arvelle Therapeutics International GmbH BiotechnologyHealth Technology Arvelle Therapeutics GmbH provides treatment for patients suffering form CNS disorders. The company was founded by Ilise Lombrado, Gregory Mark Weinhoff and Mark Altmeyer and is headquartered in Basel, Switzerland.
11
| Subsidiary | Biotechnology | 11 |
Pharvaris GmbH
 Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland.
10
| Subsidiary | Pharmaceuticals: Major | 10 |
Vico Therapeutics BV
 Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022.
10
| Holding Company | Biotechnology | 10 |
| Extinct | Financial Conglomerates | 8 | |
| Public Company | Pharmaceuticals: Major | 8 | |
The European Venture Capital Association
6
| Private Company | 6 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Martijn Kleijwegt via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| RADIUS HEALTH, INC. | Biotechnology | Director/Board Member Chief Executive Officer Corporate Officer/Principal | |
| GALAPAGOS NV | Biotechnology | Chairman Founder | |
| AURA BIOSCIENCES, INC. | Biotechnology | Director/Board Member Chairman | |
Artax Biopharma, Inc.
 Artax Biopharma, Inc. Medical SpecialtiesHealth Technology Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA. | Medical Specialties | Director of Finance/CFO Director/Board Member Director/Board Member | |
Zikani Therapeutics, Inc.
 Zikani Therapeutics, Inc. Drugstore ChainsRetail Trade Zikani Therapeutics, Inc. is a preclinical-stage company developing and commercializing novel therapeutics. The company was founded by Lawrence G. Miller and Andrew G. Myers in 2014 and is headquartered in Watertown, MA. | Drugstore Chains | Director of Finance/CFO Director/Board Member Chairman Chief Executive Officer | |
| University of Oxford | College/University | Corporate Officer/Principal Graduate Degree | |
| Karolinska Institutet | College/University | Doctorate Degree Doctorate Degree | |
Dr. Reddy's Research & Development BV
 Dr. Reddy's Research & Development BV Pharmaceuticals: MajorHealth Technology Dr. Reddy's Research & Development BV is engaged in the development and manufacture of injectable pharmaceutical products. It provides formulation, development, drug delivery, and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. The company was founded by Joost J. M. Holthuis on July 20, 1995 and is headquartered in Leiden, Netherlands. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Director/Board Member | |
| Amherst College | College/University | Undergraduate Degree Corporate Officer/Principal | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
Tel-Aviv University
 Tel-Aviv University Other Consumer ServicesConsumer Services Tel-Aviv University operates as a university in Israel. Its faculties include arts, engineering, science, humanities, law, life science, management, medicine, and social science. The company was founded in 1956 and is headquartered in Ramat Aviv, Israel. | College/University | Graduate Degree Doctorate Degree Undergraduate Degree | |
PamGene BV
 PamGene BV Pharmaceuticals: MajorHealth Technology PamGene BV provides biopharmaceutical products and clinical settings. It also provides PamChip biomarkers, such as tyrosine kinases, serine/threonine kinases, nuclear receptors, and reagent kits. The firm provides BioNavigator, a software tool for interpretation of PamChip measurements, as well as for performing data analysis for various PamChip experiments; and Evolve that enables data capture and analysis, as well as for the export of data into third party software formats. The company was founded by Tim Kievits in December 1999 and is headquartered in 's-Hertogenbosch, the Netherlands. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| ZEALAND PHARMA A/S | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| Erasmus University Rotterdam | College/University | Graduate Degree Doctorate Degree Graduate Degree Graduate Degree Doctorate Degree | |
| University of Leiden | College/University | Graduate Degree Undergraduate Degree Doctorate Degree Doctorate Degree | |
| University of Utrecht | College/University | Doctorate Degree Doctorate Degree Graduate Degree Graduate Degree Doctorate Degree Doctorate Degree | |
| Vrije Universiteit Amsterdam | College/University | Graduate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
AM-Pharma Holding BV
 AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Chief Executive Officer Director/Board Member Chief Operating Officer Corporate Officer/Principal Corporate Officer/Principal | |
| Katholieke Universiteit Leuven | College/University | Graduate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
Pontifax Management Co. Ltd.
 Pontifax Management Co. Ltd. Investment ManagersFinance Pontifax Management Co. Ltd. (Pontifax) is a venture capital firm founded in 2004 by Eliyahu Hurvitz. The firm is headquartered in Herzliya Pituach, Israel. | Investment Managers | Chief Executive Officer Founder Private Equity Investor | |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| CELLDEX THERAPEUTICS, INC. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
| Harvard Medical School | College/University | Doctorate Degree Doctorate Degree | |
DCPrime BV
 DCPrime BV Pharmaceuticals: MajorHealth Technology DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| VICORE PHARMA HOLDING AB | Pharmaceuticals: Major | Chairman Director/Board Member | |
Advent Life Sciences LLP
 Advent Life Sciences LLP BiotechnologyHealth Technology Part of Advent Venture Partners LLP, Advent Life Sciences LLP is a venture capital firm for visionary innovators. The company is based in London, UK. Advent Life Sciences has achieved its first discovery milestone in collaboration with Bristol Myers Squibb, and is focused on the journey from innovative science to an approved medicine or product. The British company has a history of delivering value and is one of the leading venture capital firms in the industry. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
LSP Advisory BV
 LSP Advisory BV Investment ManagersFinance Part of LSP Advisory Group BV, EQT Life Sciences is a healthcare investment firm based in Amsterdam, Netherlands. EQT Life Sciences has been connecting investors to inventors in the healthcare sector for over 30 years. The Dutch company has invested in close to two hundred private companies, raising billions of additional capital directed at supporting their R & D. EQT Life Sciences believes in fostering life and constant innovation in healthcare to achieve that goal. The company was founded in 1998, and Mark A. Wegter has been the CEO since then. Recently, EQT Life Sciences was acquired by EQT AB, one of the largest private equity firms in Europe, and among the top-ten private equity firms globally. | Investment Managers | Director/Board Member Chief Executive Officer | |
NeRRe Therapeutics Ltd.
 NeRRe Therapeutics Ltd. Medical DistributorsDistribution Services NeRRe Therapeutics Ltd. provides clinical and pre clinical drugs for treatment of neuronal hypersensitivity. It develops neurokinin receptor antagonists acquired from GlaxoSmithKline. The company was founded by Emiliangelo Ratti and Mike Trower in 2012 and is headquartered in Stevenage, the United Kingdom. | Medical Distributors | Director/Board Member Director/Board Member | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin Graduate Degree | |
Eloxx Pharmaceuticals Ltd.
 Eloxx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Eloxx Pharmaceuticals Ltd. provides biopharmaceutical research and development services. The firm specializes in the discovery, development, and commercialization of drug compounds for the treatment of genetic diseases. It focuses on the treatment of diseases caused by nonsense mutations, including Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, and Tay-Sachs Hurler syndrome. Its focus areas encompass clinical drug development and target drugs discovery programs. The company was founded by Silvia Noiman and Shmuel Tuvia in 2013 and is headquartered in Herzliya, Israel. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Executive Officer Director/Board Member Director/Board Member | |
| SIO GENE THERAPIES INC. | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member President | |
Axovant Sciences, Inc.
 Axovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sio Gene Therapies, Inc., Axovant Sciences, Inc. is a company that manufactures and distributes pharmaceutical products. The company is based in New York, NY. | Pharmaceuticals: Major | Director of Finance/CFO President | |
| KEROS THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Director/Board Member Director/Board Member | |
Oculis SA
 Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | Miscellaneous Commercial Services | Chairman Director/Board Member Chief Executive Officer | |
Imcheck Therapeutics SAS
 Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Arrakis Therapeutics, Inc.
 Arrakis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Founder Founder Director/Board Member | |
QurAlis Corp.
 QurAlis Corp. Pharmaceuticals: MajorHealth Technology QurAlis Corp. engages in discovering and developing new therapies for amyotrophic lateral sclerosis and other neurological diseases. It offers therapeutic programs and targets, and biomarkers. The company was founded by Clifford Woolf, Kevin Eggan, Jonathan J. Fleming, and Kasper Roet and is headquartered in North Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Tridek-One Therapeutics SAS
 Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
Arvelle Therapeutics BV
 Arvelle Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Arvelle Therapeutics BV is a Dutch biopharmaceutical company that focuses on providing innovative solutions to patients with CNS disorders. The private company is responsible for developing and commercializing an investigational anti-seizure medicine called Cenobamate in the European market. Arvelle received start-up financing of $207.80 million, which is one of the largest initial financing commitments for a European-focused biopharmaceutical company. The company is headquartered in Amsterdam, Netherlands. Arvelle was founded by Gregory Mark Weinhoff and Mark F. Altmeyer, and Mark F. Altmeyer has been the CEO since incorporation. | Miscellaneous Commercial Services | Founder Founder | |
Volastra Therapeutics, Inc.
 Volastra Therapeutics, Inc. BiotechnologyHealth Technology Volastra Therapeutics, Inc. develops novel therapies for patients with metastatic cancers. The company was founded by Lewis Cantley, Samuel Bakhoum and Olivier Elemento and is headquartered in Boston, MA. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Muna Therapeutics ApS
 Muna Therapeutics ApS Medical/Nursing ServicesHealth Services Muna Therapeutics ApS is a Danish private biopharmaceutical company that discovers and develops therapies to slow or stop neurodegenerative diseases such as Alzheimer's, frontotemporal dementia, and Parkinson's. Muna Therapeutics is based in Copenhagen, DK and was founded in 2020 by Simon Glerup and Bart de Strooper. The company focuses on identifying new medicines to preserve cognition and other brain functions and enhance resilience to these diseases. Rita Balice-Gordon has been the CEO of the company since 2020. | Medical/Nursing Services | Director/Board Member Chief Operating Officer Director/Board Member | |
| Kosa Pharma GmbH | Founder Founder | ||
Egle Therapeutics SAS
 Egle Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Egle Therapeutics SAS is a biotech company based in Paris, France. Egle Therapeutics develops first-in-class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. The French company leverages its translational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed immunocytokines acting as antagonists or as selective Treg-agonists. The company was founded in 2020 by Luc Boblet, a serial biotech entrepreneur, and Dr. Eliane Piaggio, a renowned immunologist. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member | |
| CELLNOVO | Medical Specialties | Director/Board Member Director/Board Member |
Statistieken
Internationaal
| Verenigde Staten | 15 |
| Nederland | 14 |
| Verenigd Koninkrijk | 7 |
| Frankrijk | 7 |
| Israël | 4 |
Sectoraal
| Health Technology | 27 |
| Consumer Services | 13 |
| Commercial Services | 6 |
| Finance | 3 |
| Health Services | 3 |
Operationeel
| Director/Board Member | 706 |
| Corporate Officer/Principal | 204 |
| Independent Dir/Board Member | 137 |
| Chairman | 99 |
| Director of Finance/CFO | 86 |
Sterkste connecties
| Insiders | |
|---|---|
| Daniel Geffken | 53 |
| Raj Bhikhu Parekh | 50 |
| Tomer Kariv | 46 |
| Amy Schulman | 45 |
| Raphaël Wisniewski | 45 |
| Ran Nussbaum | 38 |
| Anders Hedegaard | 30 |
| René Kuijten | 30 |
| Rémi Droller | 29 |
| Rudy Dekeyser | 29 |
| Catherine Moukheibir | 29 |
| Lionel Carnot | 27 |
| Luc Dochez | 26 |
| André-Xavier Cooreman | 25 |
| Berndt A. E. Modig | 23 |
- Beurs
- Insiders
- Martijn Kleijwegt
- Bedrijfsconnecties
